Integrity Alliance LLC. Takes $1.52 Million Position in Novo Nordisk A/S $NVO

Key Points

• Integrity Alliance LLC has invested approximately $1.52 million in Novo Nordisk A/S, acquiring 21,916 shares during the first quarter.
• Several institutional investors have increased their holdings in Novo Nordisk, with hedge funds now owning 11.54% of the company's stock.
• Analysts' ratings for Novo Nordisk A/S vary, with four analysts rating it as a "Buy" and others giving it "Hold" or "Sell" evaluations, resulting in an average rating of "Hold" with a target price of $81.00.

Integrity Alliance LLC. purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 21,916 shares of the company's stock, valued at approximately $1,522,000.

A number of other hedge funds also recently bought and sold shares of NVO. Park Square Financial Group LLC bought a new position in Novo Nordisk A/S during the fourth quarter valued at $29,000. North Capital Inc. bought a new position in Novo Nordisk A/S during the first quarter valued at $27,000. Copeland Capital Management LLC increased its position in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares during the last quarter. Stone House Investment Management LLC bought a new position in Novo Nordisk A/S during the first quarter valued at $30,000. Finally, Mascagni Wealth Management Inc. bought a new position in Novo Nordisk A/S during the fourth quarter valued at $40,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

NVO has been the topic of a number of analyst reports. Wall Street Zen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. BNP Paribas upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research report on Wednesday, August 13th. HSBC cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective on the stock. in a research report on Thursday, July 31st. Barclays restated an "equal weight" rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Finally, Dbs Bank upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Friday, August 22nd. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $81.00.

Novo Nordisk A/S Stock Up 1.2%

Novo Nordisk A/S stock traded up $0.64 during midday trading on Friday, hitting $54.94. 10,301,812 shares of the company's stock were exchanged, compared to its average volume of 14,363,850. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $138.22. The firm has a 50-day moving average of $57.96 and a two-hundred day moving average of $66.49. The company has a market cap of $245.31 billion, a PE ratio of 15.09, a P/E/G ratio of 2.06 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. As a group, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is presently 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.